Reading CRVO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRVO free→Reading CRVO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRVO free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady, but risk is elevated and the sector backdrop is a headwind. Peer multiples imply a price about 21% above where it trades (it looks cheap on this basis); the read is fair, but weakening. This assessment hinges on guidance changes and sector trends, particularly the performance of key Healthcare bellwethers. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $4.52. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $4.52 CRVO trades at 10× p/s, in line with its 10× p/s peer median. Our $5.74 fair value reflects that, medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 21% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.92x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
7 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.58 → $-0.79 (-35.0% / 30d). 1 raised, 3 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
1 PT revisions / 30d. Avg target 196.1% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$273.
How much price usually moves either way.
On a bad day, this stock has moved -$754.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,895.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Total stock risk fell by 12.2 points (from 75.7 to 63.5).
Market risk fell by 12.2 points (from 75.7 to 63.5).
Valuation label changed from 'inexpensive' to 'fair'.
risk label changed from 'high' to 'elevated'.
Risk fell. Both total stock risk and market risk decreased. The valuation label changed from "inexpensive" to "fair," indicating a shift in how the stock is viewed in terms of its price relative to its value. Additionally, the risk label changed from "high" to "elevated," reflecting a moderation in perceived risk.
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The private placement can give needed money. It impacts financial health.
Confirms one read:They completed the private placement and got good feedback from investors.
Confirms the other:There was a bad response from investors or the private placement did not happen.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Threatens: Fund operating expenses into September 2026
Financing announcement raises concerns about funding sustainability.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Definitive Agreement On June 9, 2026, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), for the private placement (the “Private Placement”) of an aggregate of 3,360,377 units (the “Units”), each Unit comprised of (i) (A) one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”), or (B)…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2017-Q2, 2017-Q3, 2023-Q3, 2024-Q3
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CRVO CervoMed Inc | Below typical Show detailsSector percentile: 23 of 100 | fair | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 86 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
CervoMed plans to start a Phase 3 trial for neflamapimod in DLB patients in H2 2026, pending funding.
CervoMed aims to fund its planned operating expenses and capital expenditure requirements into September 2026.
as of 2026-06-16
Why it matters: Starting this trial is key for CervoMed's future. It shows progress in drug development.
Confirms:Official announcement of the Phase 3 trial start date and patient recruitment.
Disproves:No announcement or delays in starting the Phase 3 trial.
Why it matters: Funding is crucial for operations. It impacts the company's ability to continue its projects.
Confirms:They announced funding that will cover costs until September 2026.
Disproves:They announced funding problems or cannot pay expenses.
Unregistered Sales of Equity Securities The disclosures set forth in
Results of Operations and Financial Condition On May 18, 2026, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the three months ended December 31, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Results of Operations and Financial Condition On March 17, 2026, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Results of Operations and Financial Condition On November 10, 2025, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended September 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to